New York, March 31, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hyperphosphatemia Treatment Global Market Report 2023" - https ...

DUBAI, United Arab Emirates, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Future Market Insights estimates that the Hyperphosphatemia Market will experience a rapid expansion between the years 2023 and 2033. By ...

Please provide your email address to receive an email when new articles are posted on . Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription The kidneys, in addition to removing toxins, ...

In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation. Current phosphate management options, including dietary ...

Due to the lack of an appropriate dosage strength, Velphoro is not approved in pediatric patients 6 years to less than 9 years of age. The Food and Drug Administration (FDA) has expanded the approval ...

Diabetes, COPD Raise Post-Kidney Transplant Readmission Rates High phosphate levels are associated with 3.3-fold increased odds of 28-day in-hospital mortality. Hyperphosphatemia predicts an increased ...

Hyperphosphatemia Linked With Mortality in Septic AKI Hyperphosphatemia was associated with more than double the risk of death from any cause. Hyperphosphatemia may portend poor outcomes in septic ...

Nov. 4, 2002 — Lanthanum carbonate (Fosrenol) is safe and effective for the treatment of hemodialysis patients with hyperphosphatemia, according to two presentations on Nov. 2 at the American Society ...

As a physician and researcher caring for people with chronic kidney disease, I see firsthand the challenges that patients undergoing dialysis face. Dialysis is life-sustaining, but it also brings ...

Excess phosphate in the blood is known as hyperphosphatemia. The most common cause is kidney disease, but other conditions can also cause phosphate levels to be out of balance. Phosphate is a chemical ...

The Prescription Drug User Fee Act target guidelines for NDA resubmissions include acknowledgment of acceptance for review within 30 days of submission, and completion of submission review within 6 ...